Journal article
Characterization of the selective indoleamine 2,3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy
- Abstract:
-
Tumors use Indoleamine 2,3-dioxygenase-1 (IDO1) as a major mechanism to induce an immunosuppressive microenvironment. IDO1 expression is upregulated in many cancers and considered to be a resistance mechanism to immune checkpoint therapies. IDO1 is induced in response to inflammatory stimuli such as IFN and promotes immune tolerance by depleting tryptophan and producing tryptophan catabolites including kynurenine in the tumor microenvironment. This leads to effector T-cell anergy and enhance...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 3.2MB)
-
- Publisher copy:
- 10.1158/1535-7163.mct-17-1104
Authors
Bibliographic Details
- Publisher:
- American Association for Cancer Research Publisher's website
- Journal:
- Molecular cancer therapeutics Journal website
- Volume:
- 17
- Issue:
- 12
- Pages:
- 2530-2542
- Publication date:
- 2018-09-19
- Acceptance date:
- 2018-09-12
- DOI:
- ISSN:
-
1535-7163 and 1538-8514
- Pmid:
-
30232146
- Source identifiers:
-
921624
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:921624
- UUID:
-
uuid:0d4fbf62-5a29-4242-9a49-40407c657439
- Local pid:
- pubs:921624
- Deposit date:
- 2018-10-03
Terms of use
- Copyright holder:
- American Association for Cancer Research
- Copyright date:
- 2018
- Notes:
- ©2018, American Association for Cancer Research. This is the accepted manuscript version of the article. The final version is available online from American Association for Cancer Research at: 10.1158/1535-7163.mct-17-1104
If you are the owner of this record, you can report an update to it here: Report update to this record